drugset / Trial / NCT00306553

Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients

NCT00306553 ↗

Phase 2 Completed Cytos Biotechnology AG
Non-randomizedSingle-groupOpen-label

Summary

The purpose of this study is to evaluate a specific cellular immune response in melanoma patients that have been vaccinated with a Melan-A VLP vaccine.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject CYT004-MelQbG10 Vaccine — —

Indications